EXPRESS: Peripheral ICOS+CD4 T cell frequency: an indicator for short-term progression in resectable advanced gastric cancer following platinum-based chemotherapy
机构：[1]Department of Orthopaedics, The First People's Hospital of Chengdu, Chengdu, Sichuan Province, 611345, China.[2]State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanwei Road 2, Xicheng District, Beijing 100050, China[3]Department of Clinical Laboratory，The Sixth Affiliated Hospital of Wenzhou Medical University& LishuiCity People’s Hospital,Lishui,Zhejiang Province, 321400, China.[4]Department of Gastrointestinal Surgery, The Sixth Affiliated Hospital of Wenzhou Medical University & Lishui City People’s Hospital, No.1188 Liyang Street,Yanquan Street,Liandu District,Lishui, Zhejiang Province, 321400, China.
Peripheral frequency of inducible T cell co-stimulator (ICOS)+CD4 T cells is associated with immunotherapy in gastric cancer (GC); however, limited studies have clarified its association with chemotherapy response.This was a prospective, pilot study. A total of 120 participants with newly diagnosed GC and 50 advanced GC patients were recruited; and their prognosis and survival were assessed. The frequency of ICOS+CD4 T cells was examined using flow cytometry.The frequency of ICOS+CD4 T cells in stage III GC patients was significantly higher than that of other stages patients. In xenograft GC animals, the frequency of ICOS+CD4 in peripheral blood was positively correlated with tumor volume in mice (P=0.0496). High frequency of peripheral ICOS+CD4 was significantly positively correlated with peripheral IFN-γ concentration. Co-culture experiments showed that the presence of GC cells increased the ratio of ICOS+CD4 T cells derived from peripheral blood. The initial peripheral frequency of ICOS+CD4 T cells in the GC progression-group was significantly lower than that in the stable-group after 3 months of platinum-based chemotherapy (P=0.0318).The frequency of ICOS+CD4 can effectively predicts the short-term progression risk for resectable advanced GC under platinum-based chemotherapy.
基金：
This project was supported by the Zhejiang Province Public Welfare Technology Research
Program (LGF21H160001), Lishui City Public Welfare Technology Application Research
Program (2023GYX61), and the Chinese Academy of Medical Sciences Innovation Fund for
Medical Sciences(2022-I2M-1-014).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类|4 区医学
小类|4 区医学：内科4 区医学：研究与实验
最新[2025]版：
大类|4 区医学
小类|4 区医学：内科4 区医学：研究与实验
第一作者：
第一作者机构：[1]Department of Orthopaedics, The First People's Hospital of Chengdu, Chengdu, Sichuan Province, 611345, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zhang Yu,Zhao Xiaodi,Ma Zhiling,et al.EXPRESS: Peripheral ICOS+CD4 T cell frequency: an indicator for short-term progression in resectable advanced gastric cancer following platinum-based chemotherapy[J].Journal Of Investigative Medicine : The Official Publication Of The American Federation For Clinical Research.2025,10815589251327133.doi:10.1177/10815589251327133.
APA：
Zhang Yu,Zhao Xiaodi,Ma Zhiling,Wang Peng,Zhang Sen&Li Jiaxin.(2025).EXPRESS: Peripheral ICOS+CD4 T cell frequency: an indicator for short-term progression in resectable advanced gastric cancer following platinum-based chemotherapy.Journal Of Investigative Medicine : The Official Publication Of The American Federation For Clinical Research,,
MLA：
Zhang Yu,et al."EXPRESS: Peripheral ICOS+CD4 T cell frequency: an indicator for short-term progression in resectable advanced gastric cancer following platinum-based chemotherapy".Journal Of Investigative Medicine : The Official Publication Of The American Federation For Clinical Research .(2025):10815589251327133
